Last updated: February 20, 2026
What Is NDC 25021-0244?
NDC 25021-0244 identifies a specific medication. According to the National Drug Code directory, this code corresponds to Vasopressin Injection, USP, 20 units/mL, 10 mL. It is approved by the FDA for vasodilatory shock, cardiac arrest, and other medical indications requiring vasoconstriction.
Market Size and Demand Drivers
Current Market Overview
- The global vasopressin market was valued at approximately USD 200 million in 2022.
- The U.S. accounts for about 50% of total demand, driven by institutional use in hospitals and emergency settings.
- Estimated annual consumption of vasopressin injections in the U.S. has grown at a compound annual growth rate (CAGR) of 4% over the past five years.
Key Demand Factors
- Increasing prevalence of septic shock, which drives the need for vasopressor agents.
- Growing adoption of vasopressin as a second-line agent in vasodilatory shock.
- Authorized in hospitals and emergency rooms with stable administration protocols.
- The COVID-19 pandemic increased hospitalizations requiring vasopressor support, temporarily boosting demand.
Competitive Landscape
Major players in vasopressin include:
| Company |
Market Share |
Product Name |
Annual Revenue (2022) |
| Bristol-Myers Squibb |
45% |
Vasostrict |
~$90 million |
| Pfizer |
30% |
Vasopressin Injection |
~$60 million |
| Others |
25% |
Alternative formulations |
~$50 million |
Note: Vasostrict is the branded version by BMS, with generic equivalents available.
Price Trends and Projections
Current Pricing
- The average wholesale price (AWP) for a 10 mL vial of vasopressin “Vasostrict” ranges from USD 50 to 70.
- Generic versions are priced approximately 20-30% lower.
- Medicare/Medicaid reimbursement rates typically range from USD 40 to 60 per vial.
Factors Impacting Future Pricing
- Patent status: Vasostrict's patent expired in 2018, increasing generic competition.
- Manufacturing costs: Changes in raw material prices influence pricing.
- Market entry of biosimilars or generics: Entry by new competitors could reduce prices by an estimated 15-25% within the next 2 years.
- Supply chain disruptions: Material shortages could temporarily elevate costs.
Price Projections (Next 3 Years)
| Year |
Projected Wholesale Price (per vial) |
Comments |
| 2023 |
USD 50-70 |
Stability with moderate competition. |
| 2024 |
USD 45-65 |
Price erosion due to increased generics. |
| 2025 |
USD 42-60 |
Market consolidation may limit decline. |
Note: These projections assume no significant regulatory or supply chain shocks.
Regulatory and Policy Influences
- The FDA has encouraged generic competition to reduce drug costs.
- Recent policies aim to promote biosimilars, which may include vasopressin biosimilar development.
- Changes in hospital reimbursement models or policies on off-label use could alter demand.
Key Market Risks
- Reduction in demand if alternative drugs (e.g., angiotensin II, norepinephrine) gain popularity.
- Price pressure from generics and biosimilars.
- Regulatory delays or approval barriers for new formulations.
Conclusion
NDC 25021-0244 (vasopressin injection) operates within a mature but steadily growing market. Price erosion is expected over the next two years due to generics, with stabilization afterward. Market size is stable, driven primarily by hospital demand for critical care applications.
Key Takeaways
- The U.S. vasopressin market was valued at approximately USD 100 million in 2022.
- Prices for vasopressin injection are likely to decline by up to 20% over the next two years due to generic competition.
- The market's growth rate is expected to remain modest, around 2-3% annually.
- Regulatory policies favoring generics will continue to influence price and market dynamics.
- Supply chain stability and new competitive entries are key uncertainties.
FAQs
1. How is the demand for vasopressin evolving?
Demand is stable but growing slowly, driven by critical care use and increased hospitalizations for septic shock.
2. What is the competitive landscape?
It consists of branded products like Vasostrict and multiple generic manufacturers, with generics gaining market share.
3. Are there upcoming regulatory changes affecting prices?
FDA policies favoring generic and biosimilar entry are likely to sustain price competition.
4. How soon could prices decline significantly?
Within 1-2 years, prices could decline by 15-25% as generics and biosimilars become more prevalent.
5. What risks could impact the market?
Demand reduction due to alternative therapies, regulatory hurdles, and supply disruptions pose risks.
References
- IMS Health. (2022). Global Vasopressor Market Report.
- U.S. Food and Drug Administration. (2018). New Drug Approvals.
- Medicaid Drug Rebate Program. (2022). Average Reimbursement Rates.
- IQVIA. (2022). Hospital and Critical Care Drug Utilization.
- FDA. (2022). Policies to Promote Generic Competition and Biosimilars.
